

Dosage recommendations for antiretroviral drugs in hepatic impairment:

	Normal dosage	Hepatic Dosage
Nucleoside reverse transcriptase inhibitors		
zidovudine	200mg q8h	No change
didanosine		
BW ≥ 60kg	400mg q24h	No change
BW <60kg	250mg q24h	No change
zalcitabine	0.75mg q8h	No change
stavudine		
BW ≥ 60kg	40mg q12 h	No change
BW <60kg	30mg q12 h	No change
lamivudine	150 mg q12h	No change
abacavir	300mg q12h	No change
tenofovir	300mg q24h	No change
emtricitibine	200mg q24h	No change
Non-nucleoside reverse transcriptase inhibitors		
nevirapine	200mg q12h	Not recommended in hepatic impairment
delavirdine	400 mg q 8 h	No data available
efavirenz	600mg q 24 h	No Change
Protease Inhibitors		
saquinavir	1200mg q8h	No change
lopinavir/ritonavir	400/100mg q12h	No change
indinavir	800mg q8h	600mg q8h
nelfinavir	1250mg q12h	No change
fosamprenavir	1400mg q12h	No data; amprenavir dose was adjusted to 600mg BID
atazanavir	400mg q24h	300mg q24h

References:

1. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. [Clin Infect Dis. 2005 Jan 1;40\(1\):174-81. Epub 2004 Dec 2.](#)